Soft Solutions picks XOsoft WANSync from CA to improve disaster recovery
NEW YORK Soft Solutions, a leading provider of web-based retail merchandise management and decision support software, announced the selection and deployment of CA’s XOsoft WANSync recovery management solution to replicate its business-critical data in multiple locations and hot sites.
France-based Soft Solutions provides uninterrupted service to over 100,000 users at multi-regional retailers regardless of time zones, as its clients—including Carrefour and CVS—are located in Europe and North America and its development work is done in Beirut, Lebanon. Since each client’s application is adapted from the standard to fit its business context, the company stated, Soft Solutions engineers must keep over 20 terabytes of critical client documentation.
“Our merchandising solutions are critical to our clients’ day-to-day operations and profitability,” stated Mounir Rahmeh, managing director of Soft Solutions. “To minimize disruption, we need to ensure that any issues are dealt with quickly and that our support services are continuously available. CA’s Recovery Management solution has provided us with the peace of mind that our applications can be recovered quickly and comprehensively, enabling our clients to keep pace with the dynamic regional and global retail sectors,” he added.
Using CA XOsoft WANSync, Soft Solutions is able to replicate all its critical data—including application source code—to a secure subsidiary office in the local area as well as a hot site in Lille, France and another replica laboratory in Cyprus. With ensured integrity of the replicated data and reduced business risk from minimizing outages, Soft Solutions can provide better global customer support and increased business productivity both at its information technology locations and at customer sites.
House investigates possibly misleading Lipitor advertisement
WASHINGTON Democrats in the House of Representatives are investigating as to whether or not consumers are being misled by advertisements for Lipitor featuring Dr. Robert Jarvik, the inventor of the artificial heart, the Associated Press reported.
Michigan Reps. John Dingell and Bart Stupak sent a letter to the drug’s manufacturer Pfizer on Monday, questioning the credibility of Jarvik, whom they believe is not certified to practice or prescribe medicine because he might not have taken the necessary tests or performed an internship.
Pfizer spokesman Chris Loder said Jarvik’s presence in the advertisements is meant to educate consumers on the importance heart health. “Dr. Jarvik is a respected health care professional and heart expert who knows how imperative it is for patients to do everything they can to keep their heart working well,” Loder said in a statement.
The representatives have requested that Pfizer turn over all of its information concerning Jarvik including its contract with him and any information about his professional qualifications.
Lipitor is the most prescribed drug in the U.S., with sales of $13.6 billion in 2006.
King ends five-year Skelaxin patent suit against CorePharma
BRISTOL, Tenn. & MIDDLESEX, N.J. King Pharmaceuticals has ended is patent lawsuit with CorePharma regarding its muscle relaxant drug Skelaxin and has signed an agreement with CorePharma related to the drug, according to Forbes.
On Jan. 2, the two companies signed an agreement under which, CorePharma will gain certain exclusive rights to Skelaxin 800 mg to market a generic version, called metaxalone and have also gained a non-exclusive license to produce and market a 400 mg version of the drug. This license will come into effect on Jan. 1, 2012.
Back in 2003, CorePharma was one of several biopharmaceutical companies to file with the Food and Drug Administration seeking permission to produce a generic. King countered by suing CorePharma and later Eon Labs and Mutual Pharmaceuticals, who also sought permission to produce a generic.
As of now, CorePharma is the only company that King Pharmaceuticals has an agreement with concerning Skelaxin. The drug is estimated to account for about $400 million in sales in 2008, according to Morgan Stanley.